OrthoPediatrics (NASDAQ:KIDS) versus SiBone (NASDAQ:SIBN) Financial Contrast

SiBone (NASDAQ:SIBN – Get Free Report) and OrthoPediatrics (NASDAQ:KIDS – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Earnings and Valuation

This table compares SiBone and OrthoPediatrics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SiBone $200.93 million 5.26 -$18.90 million ($0.31) -75.61
OrthoPediatrics $236.35 million 3.57 -$39.65 million ($1.43) -22.62

SiBone has higher earnings, but lower revenue than OrthoPediatrics. SiBone is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for SiBone and OrthoPediatrics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SiBone 1 0 7 0 2.75
OrthoPediatrics 1 1 7 0 2.67

SiBone presently has a consensus target price of $25.00, suggesting a potential upside of 6.66%. OrthoPediatrics has a consensus target price of $30.75, suggesting a potential downside of 4.95%. Given SiBone’s stronger consensus rating and higher probable upside, equities research analysts clearly believe SiBone is more favorable than OrthoPediatrics.

Institutional and Insider Ownership

98.1% of SiBone shares are owned by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are owned by institutional investors. 4.0% of SiBone shares are owned by insiders. Comparatively, 32.5% of OrthoPediatrics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares SiBone and OrthoPediatrics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SiBone -6.20% -7.57% -5.55%
OrthoPediatrics -12.83% -8.10% -5.46%

Volatility & Risk

SiBone has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Summary

SiBone beats OrthoPediatrics on 8 of the 12 factors compared between the two stocks.

About SiBone

(Get Free Report)

SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.

About OrthoPediatrics

(Get Free Report)

OrthoPediatrics Corp. develops and markets orthopedic implants and instruments designed specifically for children and adolescents. Its products support surgeons treating a range of pediatric conditions, including fractures, spinal deformities, limb-length differences and other orthopedic disorders. The company’s portfolio includes systems for trauma and deformity correction, scoliosis treatment, limb lengthening and external fixation, as well as specialized surgical instruments. It also provides related education and support for pediatric orthopedic surgeons and care teams.

Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.